Edition:
India

Scor SE (SCRYY.PK)

SCRYY.PK on OTC Markets Group

4.13USD
5 Dec 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.13
Open
$4.15
Day's High
$4.16
Day's Low
$4.11
Volume
43,607
Avg. Vol
43,105
52-wk High
$4.74
52-wk Low
$3.79

Latest Key Developments (Source: Significant Developments)

Scor: A.M. Best Confirms 'A+ Superior' Financial Strength, 'AA-' Credit Ratings
Monday, 30 Sep 2019 

Sept 30 (Reuters) - Scor SE ::REG-SCOR WELCOMES A.M. BEST’S DECISION TO CONFIRM ITS FINANCIAL STRENGTH RATING OF ‘A+ SUPERIOR’ AND THE GROUP’S ISSUER CREDIT RATING OF ‘AA-’.  Full Article

Scor Places $250 Million Catastrophe Bond, Atlas Capital UK 2019
Monday, 3 Jun 2019 

June 3 (Reuters) - SCOR SE ::SCOR SUCCESSFULLY SPONSORS A NEW USD 250 MILLION CATASTROPHE BOND, ATLAS CAPITAL UK 2019.RISK PERIOD FOR ATLAS CAPITAL UK 2019 WILL RUN FROM JUNE 1, 2019, TO MAY 31, 2023.NEW CATASTROPHE BOND, ATLAS CAPITAL UK 2019 PLC, WILL PROVIDE GROUP WITH MULTI-YEAR RISK TRANSFER CAPACITY OF USD 250 MILLION TO PROTECT ITSELF AGAINST NAMED STORMS IN U.S., EARTHQUAKES IN U.S., CANADA, WINDSTORMS IN EUROPE.  Full Article

Nuevolution's Nue20798 Shows Positive Effect On Disease Scoring
Thursday, 9 May 2019 

May 9 (Reuters) - Nuevolution Ab (Publ) ::NUEVOLUTION'S BET-BD1 SELECTIVE INHIBITOR AND CANDIDATE COMPOUND, NUE20798, SHOWS POSITIVE EFFECT ON DISEASE SCORING AND BIOMARKER LEVELS IN AN ATOPIC DERMATITIS (ECZEMA) MOUSE MODEL.NUEVOLUTION'S BET-BD1 SELECTIVE INHIBITOR AND CANDIDATE COMPOUND, NUE20798, SHOWS POSITIVE EFFECT ON DISEASE SCORING AND BIOMARKER LEVELS IN AN ATOPIC DERMATITIS (ECZEMA) MOUSE MODEL.SAYS NO NEGATIVE EFFECT WAS OBSERVED ON BLOOD PLATELET COUNT WHEN USING NUEVOLUTION'S SELECTIVE BROMODOMAIN INHIBITOR NUE20798.  Full Article

Investment fund CIAM fights back against latest criticism by reinsurer Scor
Wednesday, 27 Mar 2019 

March 27 (Reuters) - CIAM/Scor ::CIAM SAYS ITS GOAL IS NOT TO DE-STABILISE SCOR.CIAM REITERATES THAT IT WANTS TO IMPROVE GOVERNANCE AT SCOR.CIAM REITERATES THAT SCOR DID NOT PROPERLY EXAMINE COVEA'S OFFER.CIAM SAYS IT IS NOT A SPECULATIVE OR SHORT-TERM INVESTOR IN SCOR.  Full Article

French mutually-owned insurer Groupama posts higher 2018 profits and revenues
Friday, 15 Mar 2019 

March 15 (Reuters) - Groupama Assurances Mutuelles [RIC:RIC:GRPMHA.UL]::FRENCH INSURER GROUPAMA NET PROFITS UP 54 PERCENT TO 450 MILLION EUROS.FRENCH INSURER GROUPAMA ANNUAL REVENUES UP 4 PERCENT, SOLVENCY II RATIO STANDS AT 167 PERCENT.  Full Article

Scor: annual net income rises from 2017, dividend also up
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Scor SE ::SCOR CONTINUES TO GROW IN 2018, RECORDS A NET INCOME OF EUR 322 MILLION AND PROPOSES A DIVIDEND OF EUR 1.75 PER SHARE.GROUP NET INCOME IS EUR 322 MILLION FOR 2018.NET OPERATING CASH FLOWS STAND AT EUR 891 MILLION AS OF DECEMBER 31, 2018.ESTIMATED SOLVENCY RATIO STANDS AT 215%5 ON DECEMBER 31, 2018.FY GROSS WRITTEN PREMIUMS EUR 15.26 BILLION VERSUS EUR 14.79 BILLION YEAR AGO.ANNUALIZED ROE AT 5.5 PERCENT VERSUS 4.5 PERCENT YEAR AGO.THE MERGER OF THE 3SES IS ON TRACK AND IS EXPECTED TO BE COMPLETED IN Q1 2019.THE SOLVENCY CAPITAL BENEFITS OF THIS MERGER ARE ESTIMATED TO BE AROUND EUR 200 MILLION.  Full Article

Scor P&C Reinsurance Premiums Up 9.7 Percent In January
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - SCOR SE ::REG-SCOR: JANUARY 2019 P&C RENEWAL RESULTS.REG-SCOR: JANUARY 2019 P&C RENEWAL RESULTS.GROWS REINSURANCE PREMIUMS 9.7% IN A MORE FAVORABLE MARKET; EXPECTED PROFITABILITY STABLE.GREW P&C REINSURANCE PREMIUMS BY 9.7% AT CONSTANT EXCHANGE RATES AT JANUARY 2019 RENEWALS,.OVERALL RISK-ADJUSTED PRICING IMPROVED 1.3% COMPARED TO JANUARY 2018.OUTCOME OF THESE RENEWALS IS IN LINE WITH SEPTEMBER 2018 IR DAY UPDATE AT 5%-8% P.A..E EXPECT FAVORABLE MARKET CONDITIONS TO BE MORE PRONOUNCED THROUGH SPRING/SUMMER 2019 RENEWALS." - CEO.REINSURANCE PRICING IS BROADLY STABLE ACROSS NEARLY ALL LINES OF BUSINESS AND GEOGRAPHIC MARKETS.APPROXIMATELY 64% OF SCOR'S P&C REINSURANCE PREMIUMS RENEW IN JANUARY..GREW P&C REINSURANCE PREMIUMS AT JANUARY 2019 RENEWALS, FROM EUR 2.9 BILLION TO EUR 3.2 BILLION.  Full Article

Covea Says Rejects Accusations Made By Scor
Wednesday, 30 Jan 2019 

Jan 30 (Reuters) - COVEA::COVEA SAYS BOARD REJECTS ALL ACCUSATIONS MADE BY SCOR AND REAFFIRMS ITS UNANIMOUS SUPPORT FOR THIERRY DEREZ AND HIS ACTIONS.COVEA SAYS CURRENTLY HOLDS 8.17 PERCENT OF SCOR CAPITAL.  Full Article

Scor Responds To Covea's Announcement
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - SCOR SE ::RESPONDS TO COVEA'S ANNOUNCEMENT.DECIDED TO BRING COVEA'S ANNOUNCEMENT DURING MARKET HOURS ON THE DROPPED PLANNED DEAL WITH SCOR TO THE ATTENTION OF FRENCH REGULATOR AMF.SAYS HAD NOT PREVIOUSLY BEEN INFORMED OF COVÉA'S CHANGE OF POSITION ON POTENTIAL DEAL.  Full Article

Scor reiterates it does not want to become a subsidiary of Covea
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Scor SE ::REITERATES THAT SCOR DOES NOT WANT TO BECOME A SUBSIDIARY OF COVEA.SAYS CONSIDERED COVEA'S EARLIER OFFER AS A "HOSTILE" ONE.SAYS HAS NOT HAD ANY NEW BID OFFER.  Full Article

UPDATE 2-Scor CEO sets 3-year growth targets to reassure shareholders

* CEO seeks to reassure investors after he blocked takeover (Updates share price, adds comment from analyst)